Carol Gallagher
PARTNER
Cancer
ClearTech
Japan
Biography
Carol Gallagher joined New Enterprise Associates (NEA) in October 2014, where she is primarily focused on biopharma investments. Carol is a proven entrepreneur, operator and more recently investor with more than 25 years of experience in commercial, drug development and business development roles. Prior to joining NEA, she was a Venture Partner with Frazier Healthcare and she served as an independent director on multiple Boards including Aragon Pharmaceuticals, which was acquired in 2013 by Johnson and Johnson for $650 million upfront and a total consideration of $1 billion
Research Interest
Cancer
